Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. [electronic resource]
Producer: 20021210Description: 3063-7 p. digitalISSN:- 0006-4971
- Adjuvants, Immunologic -- administration & dosage
- Administration, Oral
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Apoptosis -- drug effects
- Combined Modality Therapy
- Constipation -- chemically induced
- Dose-Response Relationship, Drug
- Drug Resistance, Neoplasm
- Female
- Humans
- Lenalidomide
- Male
- Maximum Tolerated Dose
- Middle Aged
- Multiple Myeloma -- drug therapy
- Myeloma Proteins -- analysis
- Nervous System Diseases -- chemically induced
- Neutropenia -- chemically induced
- Peripheral Blood Stem Cell Transplantation
- Remission Induction
- Safety
- Salvage Therapy
- Thalidomide -- administration & dosage
- Thrombocytopenia -- chemically induced
- Transplantation, Autologous
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
There are no comments on this title.
Log in to your account to post a comment.